P53 in Biopharma: From a 40-Year Drug Hunt to Reagent Standardization
Why P53 has driven four decades of drug discovery yet remains unsolved, and how standardized recombinant P53 reagents support target validation, screening and mechanistic studies across the industry.
- Recent Advances
- Product Information
Keywords: P53, TP53 drug discovery, targeted therapy, PROTAC, reagent standardization, UA085067
Note: The full article is published in Chinese. Please refer to the Chinese version for complete experimental details, figures and product references. For product inquiries, visit www.ua-bio.com.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose 
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Business license (three certificates in one) 
